CTLA4 and neoplasm: This disparity likely reflects the differing mechanism of action for these two immune inhibitory receptors, with CTLA-4 affecting the interaction between T cells and antigen presenting cells (APCs) allowing for widespread immune activation beyond the TME including at the level of the draining lymph node as opposed to PD-1’s more localized tumor effects [10].